Aspire Biopharma Holdings (ASBP) Non-Current Debt (2023 - 2025)

Aspire Biopharma Holdings (ASBP) has 3 years of Non-Current Debt data on file, last reported at $1.5 million in Q4 2025.

• On a quarterly basis, Non-Current Debt rose 222.08% year-over-year to $1.5 million in Q4 2025; TTM through Dec 2025 was $1.5 million, a 222.08% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 222.08% from the prior year.
• Non-Current Debt for Q4 2025 stood at $1.5 million, up from $465722.0 in the prior quarter.
• Over the last five years, Non-Current Debt for ASBP reached as high as $1.5 million in Q4 2025 and fell as low as $12384.0 in Q4 2023.
• Historically, Non-Current Debt has averaged $509901.7 across 3 years, with a median of $432036.0 in 2024.
• Across the five-year window, Non-Current Debt surged 3660.68% in 2024 and soared 222.08% in 2025, its largest moves.
• Year by year, Non-Current Debt stood at $12384.0 in 2023, then jumped by 3660.68% to $465722.0 in 2024, then surged by 222.08% to $1.5 million in 2025.
• Per Business Quant data, the three most recent Non-Current Debt figures were $1.5 million in Q4 2025, $465722.0 in Q4 2024, and $436284.0 in Q3 2024.